ArticleJMIR research protocols2026
Efficacy of Tuina for Myopia in Children: Protocol for a Randomized Controlled Trial.
Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Myopia has emerged as a major threat to the visual health of adolescents worldwide. Early intervention can effectively slow down the progression of myopia in adolescents. Tuina (also known as Tui Na), a significant therapeutic method in traditional Chinese medicine, has shown promising clinical efficacy in delaying the progression of myopia; however, it lacks robust, large-scale, and standardized randomized controlled trials. Objective: This study aims to explore the efficacy and safety of tuina therapy in managing myopia in adolescents, thereby providing solid evidence for the application of tuina in the clinical treatment of myopia. Methods: This study is a multicenter randomized controlled clinical trial. A total of 62 children with myopia will be recruited from 4 hospitals and randomly assigned in a 1:1 ratio to a tuina experimental group and a drug-positive control group (tropicamide eye drops). Treatments in each group will be administered 3 times per week for a total of 8 weeks. The tuina experimental group will receive 20 minutes of tuina therapy per session, while the drug-positive control group will receive tropicamide eye drops administered every other day, with 2 drops per session. The primary outcome measures include uncorrected visual acuity and axial length, while secondary outcome measures include refractive power and accommodative amplitude. Data will be collected at baseline (week 0), on the day of completion of weeks 4 and 8 of treatment, and at the end of the 10-week follow-up period. Adverse events will be monitored and recorded throughout the study. Statisticians will be blinded. Data will be analyzed using SPSS version 28.0. Results: This study has been funded, and recruitment began in June 2025. As of December 2025, 29 participants have been enrolled, with 16 allocated to the tuina group and 13 to the drug-positive control group. Recruitment is expected to continue until October 2026. Final manuscript submission is anticipated by December 2026. Conclusions: This study aims to evaluate the efficacy and safety of tuina therapy in the treatment of adolescents with myopia. We hypothesize that the therapeutic effect of tuina therapy is noninferior to that of tropicamide eye drops, with the additional advantages of fewer side effects and stable long-term efficacy, thereby providing reliable evidence and support for the application of tuina therapy in the management of myopia in adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.